Dr. Chunrong Tong, Hematologist - Beijing, China

Dr. Chunrong Tong is a world-renowned Chief Physician and the esteemed Discipline Leader for Immunotherapy and Targeted Therapy at the prestigious GoBroad Healthcare Group in Beijing, China. Serving concurrently as the Dean of Scientific Research and the Director of the Department of Hematology I (Hematology & Oncology) at Beijing GoBroad Boren Hospital, Dr. Tong has firmly established herself as one of the foundational pioneers of immunotherapy for hematologic malignancies in China.

With an impressive medical career encompassing more than 40 years of profound clinical and research experience in hematology, she has dedicated her professional life to the comprehensive management, specialized diagnosis, and advanced treatment of highly complex blood disorders. Her deep expertise heavily focuses on targeted therapy and cellular immunotherapy, bringing renewed hope and cutting-edge solutions to patients diagnosed with severe oncological conditions such as acute leukemia, lymphoma, and multiple myeloma.

Dr. Tong is internationally recognized for her unique ability to design exceptionally precise and individualized treatment protocols. Her advanced integrative diagnostic approach masterfully combines clinical morphology, immunophenotyping, cytogenetics, FISH (Fluorescence In Situ Hybridization), molecular diagnostics, pathogen analysis, and pharmacogenomics. By leveraging these comprehensive techniques, she ensures that every single patient receives the most accurate evaluation and optimal care available in modern hematology.

Medical Expertise & Specializations

In the rapidly evolving landscape of cellular immunotherapy, Dr. Chunrong Tong leads one of the earliest and most accomplished clinical teams in China dedicated to developing and applying advanced immune cell therapies. With nearly three decades of relentless, continuous medical innovation, her elite medical team was among the absolute first in the country to successfully conduct Chimeric Antigen Receptor T-cell (CAR-T) therapy. Her pioneering medical work has fundamentally shifted global paradigms in both hematology and oncology.

Dr. Tong’s dedicated team conceptualized and developed the world’s very first rapid and lowest-dose CAR-T manufacturing strategy specifically designed for hematologic malignancies. This groundbreaking methodology achieves internationally competitive clinical efficacy while drastically reducing manufacturing costs and vastly improving overall production success rates. Her innovations have enabled the broad, sustained clinical application of these transformative treatments, earning widespread recognition and respect from oncologists, researchers, and patients worldwide.

To date, Dr. Chunrong Tong and her specialized team have administered more than 4,000 CAR-T treatments. This staggering milestone establishes her department as one of the leading single centers globally, excelling in both the overall treatment volume and the vast diversity of CAR-T biological targets utilized. Her comprehensive clinical programs cover multiple complex targets, including CD4, CD7, CD19, CD20, CD22, CD30, CD33, CD70, CD79b, BCMA, and GPRC5D. Through relentless dedication to her practice, Dr. Tong continuously innovates in advanced CAR-T sequential therapy protocols, relapse-mechanism research, and comprehensive clinical management systems. Her direct efforts significantly improve survival outcomes for high-risk, elderly, and relapsed or refractory hematologic cancer patients.

Conditions Treated

As a premier hematology expert in Beijing, Dr. Tong manages a wide spectrum of severe hematologic conditions. Her primary areas of clinical focus include:

• Acute Leukemia: Dr. Tong provides world-class oncological care for acute leukemia, including a highly specialized focus on B-cell acute lymphoblastic leukemia (B-ALL). She expertly manages patients facing post-transplant relapse, a devastating clinical challenge.
• Lymphoma: Utilizing her extensive background in cellular therapies, she addresses various complex forms of lymphoma, delivering customized, targeted treatments designed to safely eradicate malignant cells.
• Multiple Myeloma: As a leading expert in hematologic oncology, Dr. Tong offers specialized immunotherapies aimed at aggressively controlling and managing multiple myeloma.
• Relapsed/Refractory Hematologic Malignancies: Dr. Tong is highly sought after by patients whose cancers have resisted standard chemotherapy or bone marrow transplants. She utilizes cutting-edge sequential cellular strategies to overcome antigen escape.
• Solid Tumors: Expanding her therapeutic scope entirely beyond blood cancers, Dr. Tong's deep expertise also encompasses the active clinical integration of powerful immunotherapy protocols for the treatment of solid tumors.

Procedures Performed

Dr. Tong’s department at GoBroad Healthcare Group is fully equipped to perform the most advanced oncological and diagnostic procedures in the world, including:

• CAR-T Cell Therapy: Expert administration of highly targeted cellular therapy utilizing an extensive array of antigens, customized precisely to combat the specific biological markers of the patient's cancer.
• Sequential CAR-T Therapy Strategies: Implementing innovative, combined approaches, such as CD19 and CD22 sequential therapy, particularly for high-risk relapsed B-ALL, to significantly enhance long-term remission durability.
• Comprehensive Cellular Immunotherapy Platform: Administration of diverse, multi-modal cellular treatments including tumor cell vaccines, neoantigen vaccines, dendritic cell vaccines, Cytotoxic T Lymphocytes (CTLs), Cytokine-Induced Killer (CIK) cell therapy, and Natural Killer (NK) cell therapy.
• Integrated Hematologic Diagnostics: Conducting comprehensive diagnostic evaluations using morphology, advanced immunophenotyping, cytogenetics, molecular testing, and precision pharmacogenomics to perfectly tailor individualized treatment regimens.

Frequently Asked Questions (FAQ)